首页 | 本学科首页   官方微博 | 高级检索  
检索        


Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study
Institution:2. Grand Hôpital de Charleroi, Charleroi, Belgium;3. Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy;4. AOU San Martino IST, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy;6. European Institute of Oncology, Milan, Italy;5. Moffitt Cancer Center, Tampa, Florida;11. Kurashiki Central Hospital, Kurashiki, Japan;12. S.G. Moscati Hospital, Avellino, Italy;8. Roswell Park Cancer Institute, Buffalo, New York;10. Chiang Mai University, Chiang Mai, Thailand;9. LungenClinic Grosshansdorf, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Grosshansdorf, Germany;112. Novartis Institutes for BioMedical Research, Cambridge, Massachusetts;123. Gustave Roussy Cancer Campus and University Paris-Sud, Villejuif, France
Abstract:
Keywords:Buparlisib/BKM120  PI3K pathway activation  Squamous NSCLC  Nonsquamous NSCLC
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号